Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer

Breast Cancer Research and Treatment

Volumn 112, Issue SUPPL. 1, 2008, Pages 25-34

  Chlebowski, Rowan T ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Anastrozole; Aromatase inhibitors; Breast cancer; Endocrine treatment; Exemestane; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIUM CANCER; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; METASTASIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 58249113117     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0237-5     Document Type: Article

References (55)

1. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 1687 1717
2. SK Chia CH Speers CJ Bryce 2004 Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies J Clin Oncol 22 1630 1637
3. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746
4. Mansell J, Monypenny IJ, Skene AI et al (2006) Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res Treat 100 (abstract 2091)
5. L Mauriac A Keshaviah M Debled 2007 Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Ann Oncol 18 859 867
6. C Schairer PJ Mink L Carroll SS Devesa 2004 Probabilities of death from breast cancer and other causes among female breast cancer patients J Natl Cancer Inst 96 1311 1321
7. MG Lê R Arriagada M Spielmann 2002 Prognostic factors for death after isolated local recurrence in patients with early-stage breast carcinoma Cancer 94 2813 2820
8. Ng RCH, Pond GR, Tang PA et al (2006) Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5 y overall survival (OS) in adjuvant systemic trials of early stage breast cancer. Breast Cancer Res Treat 100 (abstract 2077)
9. Melisko M, Lin A, Rugo H (2007) Adjuvant therapy for early stage breast cancer (EBC): distant disease-free survival (DDFS) as a predictor of overall survival (OS). J Clin Oncol 25:(18S) (abstract 583)
10. M Baum AU Budzar J Cuzick 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial Lancet 359 2131 2139 Erratum in Lancet 2002; 360:1520
11. B Thürlimann On Behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757
12. B Fisher J Dignam J Bryant 1996 Five years versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 88 1529 1542
13. EP Winer C Hudis HJ Burstein 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 619 629
14. AG Rieber RL Theriault 2005 Aromatase inhibitors in postmenopausal breast cancer patients J Natl Compr Cancer Netw 3 309 314
15. A Goldhirsch WC Wood RD Gelber 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144
16. Coombes RC, Hall E, Gibson LJ et al, Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
17. RC Coombes LS Kilburn CF Snowdon 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570
18. M Kaufmann W Jonat J Hilfrich 2006 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study J Clin Oncol 25 19 2664 2670
19. F Boccardo A Rubagotti P Guglielmini 2006 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial Ann Oncol 17 vii 10 14
20. SE Jones 2006 Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/tamoxifen exemestane adjuvant multicenter trials Clin Breast Cancer 6 suppl. 2 S41 S4
21. Jakesz R, Gnant M, Greil R et al (2005) The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 94:(suppl. 1):S10 (abstract 13)
22. R Jakesz W Jonat M Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462
23. PE Goss JN Ingle JL Pater 2008 Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen J Clin Oncol 26 12 1948 1955
24. EP Mamounas JH Jeong DL Wickerham 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial J Clin Oncol 26 12 1965 1971
25. R Jakesz R Greil M Gnant 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 24 1845 1853
26. A Howell J Cuzick M Baum 2005 Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62
27. ATAC Trialist's Group 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 1 45 53
28. AS Coates A Keshaviah B Thürlimann 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492
29. G Viale A Giobbie-Hurder MM Regan 2008 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole Clin Oncol 26 5569 5575
30. M Dowsett C Allred J Knox 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial J Clin Oncol 26 7 1059 1065
31. BB Rasmussen MM Regan AE Lykkesfeldt 2008 Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial Lancet Oncol 9 1 23 28
32. Coombes RC, Hall E, Snowdon CF et al (2004) The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen updated survival analysis. Breast Cancer Res Treat 88:S7 (abstract 3)
33. Peto R et al ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women preliminary results. Presented at the 30th annual San Antonio breast cancer symposium, San Antonio, TX, 13-16 December 2007 (abstract 48)
34. Gray RG (2008) aTTom (adjuvant tamoxifen-to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-preliminary results. Proc ASCO (abstract 513)
35. Houghton J (2006) On Behalf of the ATAC Trialists' Group. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T)-data reported on behalf of the ATAC ('Arimidex', Tamoxifen, alone or in combination) Trialists' Group. Ann Oncol 17:(suppl. 9):ix 94 (abstract 243)
36. W Jonat C Mundrhenke 2007 The FACE trial: letrozole or anastrozole as initial adjuvant therapy? Cancer Invest 25 1 14 18
37. J Cuzick P Sasieni A Howell 2006 Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 94 4 460 464
38. C Fontaine A Meulemans M Huizing 2008 Tolerance of adjuvant letrozole outside of clinical trials Breast 17 4 376 381
39. RE Coleman WW Bolten M Lansdown 2008 Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations Cancer Treat Res 34 3 275 282
40. ATAC Trialists' Group 2006 Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633 643
41. DM Herrington KP Klein 2001 Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function Womens Health Issues 11 2 95 102
42. RR Love DA Wiebe PA Newcomb 1991 Effects of tamoxifen on cardiovascular risk factors in postmenopausal women Ann Intern Med 115 860 864
43. RS Braithwaite RT Chlebowski J Lau 2003 Meta-analysis of vascular and neoplastic events associated with tamoxifen J Gen Intern Med 18 937 947
44. RT Chlebowski G Anderson M Geller N Col 2006 Coronary heart disease and stroke with aromatase inhibitor, tamoxifen and menopausal hormone therapy use Clin Breast Cancer 6 suppl. 2 S58 S64
45. J Cuzick J Forbes R Edwards 2002 First results from the International Breast Cancer Intervention Study (IBIS): a randomized prevention trial Lancet 360 817 824
46. SE Reis JP Costantino DL Wickerham 2001 Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators J Natl Cancer Inst 93 16 21
47. C Harper-Wynne G Ross N Sacks 2002 Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention Cancer Epidemiol Biomark Prev 11 614 621
48. PE Lønning J Geisler LE Krag 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer J Clin Oncol 23 5126 5137
49. J Lester D Dodwell E McCloskey R Coleman 2005 The causes and treatment of bone loss associated with carcinoma of the breast Cancer Treat Rev 31 115 142
50. S Epstein 2006 Update of current therapeutic options for the treatment of postmenopausal osteoporosis Clin Ther 28 151 173
51. Brufsky A, Dong M, Lund K et al Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). San Antonio breast cancer symposium 2006 (abstract 5060)
52. Bundred N, Campbell I, Coleman R et al (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). Eur J Can suppl 4:48 (abstract 12)
53. Singh S, Cuzick J, Edwards R et al (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from the bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Breast Cancer Res Treat 106:(suppl. 1):S9 (abstract 28)
54. Cuzick J, Wale C (2006) On Behalf of the ATAC Trialists' Group A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years. Breast Cancer Res Treat 100 (abstract 104)
55. S Duffy TL Jackson M Lansdown 2006 The ATAC ('Arimidex', Tamoxifen, alone or in combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment Hum Reprod 21 2 545 553